BRPI0908334A2 - kit, composição, produto ou medicamento para tratar comprometimento cognitivo - Google Patents

kit, composição, produto ou medicamento para tratar comprometimento cognitivo

Info

Publication number
BRPI0908334A2
BRPI0908334A2 BRPI0908334A BRPI0908334A BRPI0908334A2 BR PI0908334 A2 BRPI0908334 A2 BR PI0908334A2 BR PI0908334 A BRPI0908334 A BR PI0908334A BR PI0908334 A BRPI0908334 A BR PI0908334A BR PI0908334 A2 BRPI0908334 A2 BR PI0908334A2
Authority
BR
Brazil
Prior art keywords
medication
kit
composition
product
cognitive impairment
Prior art date
Application number
BRPI0908334A
Other languages
English (en)
Inventor
Saitoh Kenichi
Yamaguchi Yoshimasa
Matsuno Yoshiyuki
Original Assignee
Zenyaku Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenyaku Kogyo Kk filed Critical Zenyaku Kogyo Kk
Publication of BRPI0908334A2 publication Critical patent/BRPI0908334A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0908334A 2008-02-28 2009-02-27 kit, composição, produto ou medicamento para tratar comprometimento cognitivo BRPI0908334A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/039,192 US20090221554A1 (en) 2008-02-28 2008-02-28 Method of treating cognitive impairment
PCT/JP2009/000918 WO2009107401A1 (en) 2008-02-28 2009-02-27 Kit, composition, product or medicament for treating cognitive impairment

Publications (1)

Publication Number Publication Date
BRPI0908334A2 true BRPI0908334A2 (pt) 2018-01-30

Family

ID=41013653

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908334A BRPI0908334A2 (pt) 2008-02-28 2009-02-27 kit, composição, produto ou medicamento para tratar comprometimento cognitivo

Country Status (14)

Country Link
US (3) US20090221554A1 (pt)
EP (1) EP2257290A4 (pt)
JP (1) JP5666910B2 (pt)
KR (1) KR101325324B1 (pt)
CN (1) CN101969948B (pt)
AU (1) AU2009219546A1 (pt)
BR (1) BRPI0908334A2 (pt)
CA (1) CA2716757C (pt)
EA (1) EA023751B1 (pt)
IL (1) IL207811A0 (pt)
MX (1) MX2010009390A (pt)
TW (1) TWI501767B (pt)
WO (1) WO2009107401A1 (pt)
ZA (1) ZA201006087B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100338074C (zh) * 2001-01-30 2007-09-19 全药工业株式会社 杂环化合物和以其为有效成分的脑机能改善剂
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
WO2010077852A2 (en) * 2008-12-15 2010-07-08 The Regents Of The University Of California Method of inducing cleavage of amyloid precursor protein to form a novel fragment
US20100256173A1 (en) * 2009-04-02 2010-10-07 Eckard Weber Method of Treating Cognitive Impairment
JP2012524097A (ja) * 2009-04-14 2012-10-11 キム， ニコラス グリーン， プロａｄａｍ１０セクレターゼ及び／又はベータセクレターゼレベルの減少方法
US20100298348A1 (en) * 2009-05-11 2010-11-25 Kim Nicholas Green Method of Decreasing Ubiquitylated Protein Levels
WO2012094612A1 (en) * 2011-01-07 2012-07-12 Zenyaku Kogyo Kabushikikaisha Method of treating essential tremor
FR2974729B1 (fr) * 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
AU2013327450B2 (en) * 2012-10-05 2018-07-12 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
KR101484405B1 (ko) * 2013-08-14 2015-01-19 서울대학교산학협력단 Ｎｉｎｊｕｒｉｎ１ 결핍 유래의 강박증 예방 또는 치료용 약학적 조성물
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7464591B2 (ja) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物
KR20210072569A (ko) * 2019-12-09 2021-06-17 주식회사 종근당 도네페질 및 메만틴을 포함하는 복합 제제

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
JPH10259126A (ja) * 1997-01-17 1998-09-29 Takeda Chem Ind Ltd アルツハイマー病治療・予防剤
US6262081B1 (en) * 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
AU754719B2 (en) * 1998-08-31 2002-11-21 Merck & Co., Inc. Method of treating neurodegenerative diseases
WO2001009131A1 (en) * 1999-07-30 2001-02-08 Zenyaku Kogyo Kabushiki Kaisha Azaindolizinone derivatives and cerebral function improvers containing the same as the active ingredient
CN100338074C (zh) * 2001-01-30 2007-09-19 全药工业株式会社 杂环化合物和以其为有效成分的脑机能改善剂
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
DE60216275T2 (de) * 2001-05-25 2007-06-21 Schering Corp. Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
WO2003105830A1 (ja) * 2002-06-14 2003-12-24 富山化学工業株式会社 脳機能を改善する医薬組成物および脳機能を改善するための方法
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
AU2003274353B2 (en) * 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
CA2597566A1 (en) * 2005-02-11 2006-08-17 Stephen Wills Treating microvasculature diseases with acetyl cholinesterase inhibitors
ATE511843T1 (de) * 2005-04-04 2011-06-15 Eisai R&D Man Co Ltd Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz
JP2009506069A (ja) * 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
AR061637A1 (es) * 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
JP5160764B2 (ja) * 2006-10-13 2013-03-13 全薬工業株式会社 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment

Also Published As

Publication number Publication date
CA2716757C (en) 2014-06-17
CA2716757A1 (en) 2009-09-03
JP2011513200A (ja) 2011-04-28
CN101969948B (zh) 2014-07-16
EA201071006A1 (ru) 2011-02-28
TWI501767B (zh) 2015-10-01
CN101969948A (zh) 2011-02-09
US20110059998A1 (en) 2011-03-10
WO2009107401A1 (en) 2009-09-03
EA023751B1 (ru) 2016-07-29
US20120083486A1 (en) 2012-04-05
EP2257290A1 (en) 2010-12-08
MX2010009390A (es) 2010-11-30
US20090221554A1 (en) 2009-09-03
IL207811A0 (en) 2010-12-30
KR20100121500A (ko) 2010-11-17
JP5666910B2 (ja) 2015-02-12
KR101325324B1 (ko) 2013-11-08
AU2009219546A1 (en) 2009-09-03
TW200942236A (en) 2009-10-16
EP2257290A4 (en) 2013-07-31
ZA201006087B (en) 2011-10-26

Similar Documents

Publication Publication Date Title
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
BRPI0814745A2 (pt) Composição de produto.
PT2729151T (pt) Composição farmacêutica, métodos de tratamento e suas utilizações
BR112013007684A2 (pt) composição de múltiplas fases para cuidado pessoal, para cuidado doméstico ou para cuidado com a saúde
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
CO6791606A2 (es) Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BRPI0908428A2 (pt) uso de ranozalina para tratar a dor.
BRPI0914614A2 (pt) 2-arilaminoquinazolinas para tratar doenças proliferativas
EP2381760A4 (en) CORN PROTEIN COMPOSITION
BRPI0905369A2 (pt) Composição farmacêutica, composição e kit compartimentado
BRPI0812146A2 (pt) Processo, mistura, utilização da mistura, borracha sintética
BR112013003529A2 (pt) "composição aerada, composição de tratamento capilar método para o tratamento capilar"
ZA201006087B (en) Kit, composition, product or medicament for treating cognitive impairment
BRPI0815246A2 (pt) Composição de catalisador
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0918344A2 (pt) composição catalítica
DE112010002714A5 (de) Polymere enthaltend substituierte anthracenyleinheiten, blends enthaltend diese polymere sowie vorrichtungen enthaltend diese polymere oder blends
EP2236149A4 (en) MEDICAL COMPOSITION
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BR112013006232A2 (pt) processo de tratamento cosmético, composto e composição cosmética
BRPI0922347A2 (pt) métodos para prevenir ou reduzir carcinogênese de colón

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]